PCR Online

PCR meets the requirements of patients by enabling the interventional cardiovascular community to exchange knowledge.

Local

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#181040

France

#31880

Health/Medicine

#95

Traffic sources

Monthly visitors

Articles

Percutaneous coronary treatment with Bioadaptor implant vs drug-eluting stent : 2-year outcomes from BIOADAPTOR RCT

Mar 8, 2025 | pcronline.com | Giovanni Occhipinti |Salvatore Brugaletta

Selected in JACC: Cardiovascular Interventions by G. Occhipinti , S. Brugaletta At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent. References Authors Shigeru Saito, Johan Bennett, Holger M.
A patient with ISR: what is the role of DCB today?

Nov 29, 2024 | pcronline.com | Andreas Baumbach |Fernando Alfonso |Azeem Latib

Participate in this live event Register with your My PCR account, add it to your calendar and receive automatic reminders.
TCT 2024: A large-scale, randomized trial of orbital atherectomy vs. conventional balloon angioplasty in severely calcified coronary arteries prior to DES implantation (ECLIPSE) | PCRonline

Oct 30, 2024 | pcronline.com | Nicola Ryan

Reported from TCT 2024 Nicola Ryan provides her take on the ECLIPSE trial presented by Ajay J. Kirtane at TCT 2024 in Washington. ECLIPSE compared orbital atherectomy with conventional balloon angioplasty in patients with calcified coronary lesions with clinical equipoise for either strategy. Why this study – the rationale/objective? Coronary calcium is increasingly encountered in clinical practice and is associated with increased PCI complexity.
TCT 2024: Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis (TAVR UNLOAD) | PCRonline

Oct 28, 2024 | pcronline.com | Mirvat Alasnag |Nicolas Van Mieghem

Reported from TCT 2024 Mirvat Alasnag interviews Nicolas M. Van Mieghem about the results of the TAVR UNLOAD trial he presented at the TCT Conference 2024. TAVR for moderate AS in Heart Failure with reduced Ejection Fraction (HFrEF) patients on GDMT was safe and improved quality of life at one year but didn't affect the primary endpoint at 23 months.
Hypertension - the silver bullet of medicine

Oct 6, 2024 | pcronline.com | Andrew Sharp

In this special report, learn about The Essentials of Hypertension Hypertension is the number one cause of years of life lost, and, perhaps more importantly, years of healthy living lost. It causes at least half of all heart attacks and strokes and is the major driver of heart failure. As cardiologists, much of our working life is spent dealing with the downstream consequences of hypertension...
Why hypertension is a major unresolved problem

Oct 2, 2024 | pcronline.com | Sofie Brouwers

Hypertension: A major global health challenge Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers. Hypertension remains one of today’s major global health challenges despite the existence of adequate tools for screening, diagnosis, treatment, and ongoing advances in public health initiatives.
ESC Congress 2024: REC-CAGEFREE I - Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions: a multicenter, non-inferiority trial | PCRonline

Sep 8, 2024 | pcronline.com | Mirvat Alasnag

Reported from ESC Congress 2024Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London. BackgroundThere has been growing enthusiasm for drug-coated balloon (DCB) technology in recent years. Evidence has mounted from multiple trials such as the BASKET-SMALL 2, PICCOLETO II, and AGENT IDE trials.
ESC Congress 2024: RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure | PCRonline

Sep 1, 2024 | pcronline.com | Nicola Ryan

Reported from ESC Congress 2024Nicola Ryan provides her take on the RESHAPE-HF2 trialpresented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM. The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical therapy in patients with heart failure and moderate to severe functional mitral regurgitation. PICOT analysis of RESHAPE-HF2.
ESC Congress 2024: MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary mitral regurgitation treated by transcatheter edge-to-edge repair. | PCRonline

Aug 31, 2024 | pcronline.com | Jonathan Curio

Reported from ESC Congress 2024Jonathan Curio provides his take on the MitrAI score study which was presented by Luigi Biasco at ESC Congress 2024 in London. Graphic summary of key aspects of the MitraAI score study. Courtesy of Jonathan Curio. Source: PCRonline.comGraphic summary of key aspects of the MitraAI score study. Courtesy of Jonathan Curio. Source: PCRonline.comWhy this study?
ESC Congress 2024 - ESC Guidelines: chronic coronary syndromes | PCRonline

Aug 30, 2024 | pcronline.com | Julia Grapsa

Reported from ESC Congress 2024Julia Grapsa provides her take on the Chronic Coronary Syndromes (CCS) Guidelines which were presented by Felicita Andreotti and Christiaan Vrints at ESC Congress 2024 in London.